These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

679 related items for PubMed ID: 29258679

  • 1. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.
    Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.
    Eur Urol; 2018 May; 73(5):715-723. PubMed ID: 29258679
    [Abstract] [Full Text] [Related]

  • 2. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [Abstract] [Full Text] [Related]

  • 3. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
    Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, Salvi S, Castellano D, Romanel A, Lolli C, Casadio V, Gurioli G, Amadori D, Font A, Vazquez-Estevez S, González Del Alba A, Mellado B, Fernandez-Calvo O, Méndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez A, Santander C, Sáez MI, Puente J, Gasi Tandefelt D, Wingate A, Dearnaley D, PREMIERE Collaborators, Spanish Oncology Genitourinary Group, Demichelis F, De Giorgi U, Gonzalez-Billalabeitia E, Attard G.
    Ann Oncol; 2017 Jul 01; 28(7):1508-1516. PubMed ID: 28472366
    [Abstract] [Full Text] [Related]

  • 4. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK, Thoene S, Bietenbeck A, Nawroth R, Tauber R, Thalgott M, Schmid S, Secci R, Retz M, Gschwend JE, Ruland J, Winter C, Heck MM.
    Eur Urol; 2017 Nov 01; 72(5):828-834. PubMed ID: 28818355
    [Abstract] [Full Text] [Related]

  • 5. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
    Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Denmeade SR, Pienta KJ, Paller CJ, Carducci MA, Eisenberger MA, Luo J.
    J Clin Oncol; 2017 Jul 01; 35(19):2149-2156. PubMed ID: 28384066
    [Abstract] [Full Text] [Related]

  • 6. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J, Rodrigues DN, Sharp A, Sun S, Lorente D, Riisnaes R, Figueiredo I, Zafeiriou Z, Rescigno P, de Bono JS, Plymate SR.
    Eur Urol; 2016 Oct 01; 70(4):599-608. PubMed ID: 27117751
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB.
    Eur Urol; 2015 Mar 01; 67(3):470-9. PubMed ID: 25306226
    [Abstract] [Full Text] [Related]

  • 10. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
    Nakazawa M, Antonarakis ES, Luo J.
    Horm Cancer; 2014 Oct 01; 5(5):265-73. PubMed ID: 25048254
    [Abstract] [Full Text] [Related]

  • 11. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.
    Liu C, Armstrong C, Zhu Y, Lou W, Gao AC.
    Oncotarget; 2016 May 31; 7(22):32210-20. PubMed ID: 27049719
    [Abstract] [Full Text] [Related]

  • 12. TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.
    De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY.
    Clin Cancer Res; 2019 Mar 15; 25(6):1766-1773. PubMed ID: 30209161
    [Abstract] [Full Text] [Related]

  • 13. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
    Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ, Rasmussen J, Thornburg B, Berry WR, Wilder RS, Lu C, Chen Y, Silberstein JL, Kemeny G, Galletti G, Somarelli JA, Gupta S, Gregory SG, Scher HI, Dittamore R, Tagawa ST, Antonarakis ES, George DJ.
    J Clin Oncol; 2019 May 01; 37(13):1120-1129. PubMed ID: 30865549
    [Abstract] [Full Text] [Related]

  • 14. Persistent androgen receptor addiction in castration-resistant prostate cancer.
    Schweizer MT, Yu EY.
    J Hematol Oncol; 2015 Nov 13; 8():128. PubMed ID: 26566796
    [Abstract] [Full Text] [Related]

  • 15. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
    Graham L, Schweizer MT.
    Med Oncol; 2016 May 13; 33(5):44. PubMed ID: 27042852
    [Abstract] [Full Text] [Related]

  • 16. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.
    Eur Urol; 2015 Aug 13; 68(2):228-35. PubMed ID: 24837187
    [Abstract] [Full Text] [Related]

  • 17. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C, Schnoeller TJ, Luedeke M, Steinestel K, Boegemann M, Schrader AJ, Steinestel J.
    Eur Urol; 2017 Jan 13; 71(1):1-3. PubMed ID: 27471164
    [Abstract] [Full Text] [Related]

  • 18. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
    Hung J, Taylor AR, Divine GW, Hafron JM, Hwang C.
    Clin Genitourin Cancer; 2016 Oct 13; 14(5):381-388. PubMed ID: 27157640
    [Abstract] [Full Text] [Related]

  • 19. Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.
    Lim AC, Attard G.
    Curr Drug Targets; 2013 Apr 13; 14(4):408-19. PubMed ID: 23565754
    [Abstract] [Full Text] [Related]

  • 20. Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients.
    Maillet D, Allioli N, Peron J, Plesa A, Decaussin-Petrucci M, Tartas S, Ruffion A, Crouzet S, Rimokh R, Gillet PG, Freyer G, Vlaeminck-Guillem V.
    Eur Urol Oncol; 2021 Aug 13; 4(4):609-617. PubMed ID: 31676281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.